1-(aminomethyl)-N,N-dimethylcyclopropan-1-amine | 176445-82-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-(aminomethyl)-N,N-dimethylcyclopropan-1-amine
• CAS: 176445-82-2
• 化学式: C₆H₁₄N₂
• 分子量: 114.191
• InChiKey: OCITTXIQCCPLRK-UHFFFAOYSA-N

物化性质

• 沸点：
  121.5±8.0 °C(Predicted)
• 密度：
  0.95±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Ethoxycarbonyl 4-amino-5-chloro-2-methoxybenzoate 、 1-(aminomethyl)-N,N-dimethylcyclopropan-1-amine 以 四氢呋喃 为溶剂， 生成 4-amino-5-chloro-N-[[1-(dimethylamino)cyclopropyl]methyl]-2-methoxybenzamide
  参考文献：
  名称：

  Serotoninergic properties of new conformationally restricted benzamides

  摘要：

  A new series of benzamides derived from metoclopramide have been synthesized, in which the vicinal carbon of the basic nitrogen atom of the ethyl chain is situated on the C-3, C-4, C-5 and C-6 rings. The diamino derivatives were prepared through Strecker's reaction from the corresponding ketones except for the cyclopropyl derivatives where 1-ethoxy-1-trimethylsiloxy cyclopropane was used as the starting material. The benzamides were prepared using the mixed anhydride method. They were tested in binding assays for D-2, 5-HT3 and 5-HT4 receptors. The results show a marked increase in the selectivity and potency of these derivatives for 5-HT3 receptors with regard to metoclopramide (compound 1d: 5-HT3 K-i = 9.03 nM; 5-HT4 K-i > 5000; D-2 K-i > 5000). The influences of steric hindrance and hydrophobic properties on the affinity of benzamide derivatives for 5-HT3 receptors were also emphasized by these data. The X-ray crystal structure of compound 1d was compared with that of the minimal energy conformer of BRL 24682, a reference 5-HT3 receptor antagonist benzamide, determined using the Random Search program. Superimposition of the two structures showed a suitable fit between the pharmacophore groups previously determined to be important for 5-HT3 receptor antagonists. On the other hand, the hydrophobic parts of the basic moieties had different spatial occupancies.

  DOI：

  10.1016/0223-5234(96)89139-2
• 作为产物：
  描述：

  1-(二甲基氨基)环丙烷甲酰胺 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 1-(aminomethyl)-N,N-dimethylcyclopropan-1-amine
  参考文献：
  名称：

  Serotoninergic properties of new conformationally restricted benzamides

  摘要：

  A new series of benzamides derived from metoclopramide have been synthesized, in which the vicinal carbon of the basic nitrogen atom of the ethyl chain is situated on the C-3, C-4, C-5 and C-6 rings. The diamino derivatives were prepared through Strecker's reaction from the corresponding ketones except for the cyclopropyl derivatives where 1-ethoxy-1-trimethylsiloxy cyclopropane was used as the starting material. The benzamides were prepared using the mixed anhydride method. They were tested in binding assays for D-2, 5-HT3 and 5-HT4 receptors. The results show a marked increase in the selectivity and potency of these derivatives for 5-HT3 receptors with regard to metoclopramide (compound 1d: 5-HT3 K-i = 9.03 nM; 5-HT4 K-i > 5000; D-2 K-i > 5000). The influences of steric hindrance and hydrophobic properties on the affinity of benzamide derivatives for 5-HT3 receptors were also emphasized by these data. The X-ray crystal structure of compound 1d was compared with that of the minimal energy conformer of BRL 24682, a reference 5-HT3 receptor antagonist benzamide, determined using the Random Search program. Superimposition of the two structures showed a suitable fit between the pharmacophore groups previously determined to be important for 5-HT3 receptor antagonists. On the other hand, the hydrophobic parts of the basic moieties had different spatial occupancies.

  DOI：

  10.1016/0223-5234(96)89139-2

文献信息

• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSÉS ORGANIQUES
  申请人：NOVARTIS AG

  公开号：WO2005051895A1

  公开（公告）日：2005-06-09

  Disclosed are δ-amino-Ϝ-hydroxy-ω-aryl-alkanoic acid amide compounds of formula (I) and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

  揭示了具有抑制肾素作用的δ-氨基-Ϝ-羟基-ω-芳基-烷酸酰胺化合物的化学式(I)及其盐。还揭示了包含这些化合物的药物组合物以及用于治疗高血压、动脉粥样硬化、不稳定性冠状动脉综合征、充血性心力衰竭、心肌肥大、心脏纤维化、心肌病后梗死、不稳定性冠状动脉综合征、舒张功能障碍、慢性肾脏疾病、肝纤维化、糖尿病引起的并发症（如肾病、血管病和神经病变）、冠状动脉疾病、血管成形术后再狭窄、眼内压升高、青光眼、异常血管生长、高醛固酮症、认知障碍、阿尔茨海默病、痴呆、焦虑状态和认知障碍的治疗方法。
• Gram-positive carbapenem antibacterials and processes for their preparation
  申请人：Choi Woo-Baeg

  公开号：US20060074070A1

  公开（公告）日：2006-04-06

  The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment. The present invention is also in the field of synthetic organic chemistry and is specifically provides an improved method of synthesis of β-methyl carbapenems which are useful as antibacterial agents.

  本发明提供了β-甲基碳青霉烯化合物和制药组合物，可用于治疗细菌感染，并提供了使用这些化合物和/或组合物治疗此类感染的方法。本发明包括向需要此类治疗的宿主施用β-碳青霉烯化合物或盐和/或前药的有效量。本发明还属于合成有机化学领域，特别提供了一种改进的β-甲基碳青霉烯合成方法，其可用作抗菌剂。
• Organic compounds
  申请人：Baeschlin Kaspar Daniel

  公开号：US20070135498A1

  公开（公告）日：2007-06-14

  Disclosed are δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide compounds of formula (I) and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

  本发明涉及一种具有肾素抑制作用的δ-氨基-γ-羟基-ω-芳基-脂肪酸酰胺化合物(I)及其盐。还公开了包含这些化合物的制药组合物以及用于治疗高血压、动脉粥样硬化、不稳定性冠状动脉综合征、充血性心力衰竭、心脏肥大、心脏纤维化、心肌梗死后的心肌病、舒张功能障碍、慢性肾脏病、肝纤维化、糖尿病引起的并发症（如肾病、血管病和神经病）、冠状血管疾病、血管成形术后再狭窄、眼内压增高、青光眼、异常血管生长、高醛固酮症、认知障碍、老年痴呆症、焦虑状态和认知障碍的治疗方法。
• ORGANIC COMPOUNDS
  申请人：Baeschlin Daniel Kaspar

  公开号：US20090253703A1

  公开（公告）日：2009-10-08

  Disclosed are δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide compounds of formula (I) and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

  本发明公开了式(I)的δ-氨基-γ-羟基-ω-芳基-脂肪酸酰胺化合物及其盐，具有抑制肾素的特性。本发明还公开了包含这些化合物的药物组合物和治疗高血压、动脉粥样硬化、不稳定性冠状动脉综合症、充血性心力衰竭、心脏肥大、心脏纤维化、心肌梗死后心肌病、舒张功能障碍、慢性肾脏病、肝纤维化、糖尿病引起的并发症，如肾病、血管病和神经病变、冠状动脉疾病、血管成形术后再狭窄、眼内压升高、青光眼、异常血管生长、高醛固酮症、认知障碍、阿尔茨海默病、痴呆、焦虑状态和认知障碍的治疗方法。
• GRAM-POSITIVE CARBAPENEM ANTIBACTERIALS AND PROCESSES FOR THEIR PREPARATION
  申请人：Choi Woo-Baeg

  公开号：US20100075945A1

  公开（公告）日：2010-03-25

  The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment. The present invention is also in the field of synthetic organic chemistry and is specifically provides an improved method of synthesis of β-methyl carbapenems which are useful as antibacterial agents.

  本发明提供了β-甲基碳青霉烯化合物和制药组合物，可用于治疗细菌感染，并提供使用这些化合物和/或组合物治疗此类感染的方法。本发明包括向需要此类治疗的宿主投与有效量的碳青霉烯化合物或盐和/或前药。本发明还属于合成有机化学领域，特别提供了一种改进的β-甲基碳青霉烯化合物合成方法，该方法可用作抗菌剂。